60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
Rhea-AI Summary
60 Degrees Pharmaceuticals (NASDAQ:SXTP) reported first quarter 2026 results for the period ended March 31, 2026.
Net product revenues were approximately $162 thousand, down about 1% year over year. Gross profit was $76 thousand. Operating expenses rose to $2.17 million, and net loss attributable to common shareholders was $2.21 million, or $1.28 per share.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- Net product revenues decreased ~1% to $162 thousand
- Gross profit declined to $76 thousand from $90 thousand
- Operating expenses increased to $2.17 million from $2.09 million
- Net loss widened to $2.21 million from $2.00 million
Key Figures
Market Reality Check
Peers on Argus
SXTP was down 2.67% while momentum‑screened peers ADTX, KTTA, and SILO were all up between 3–6%. In the sector list, most peers (TTNP, KTTA, ARTL, PLRZ) showed declines with only SILO positive, pointing to stock‑specific pressure rather than a unified sector move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 13 | Q3 2025 earnings | Negative | -4.9% | Revenue growth but gross loss, higher expenses, and sizable net loss. |
| Aug 13 | Q2 2025 earnings | Positive | -3.0% | Improved gross profit and lower operating expenses despite revenue decline. |
| May 15 | Q1 2025 earnings | Negative | +14.9% | Strong revenue and gross profit growth but swing to net loss vs prior income. |
| Nov 14 | Q3 2024 earnings | Positive | -3.1% | Significant sales growth and positive gross profit but higher expenses and loss. |
| Aug 14 | Q2 2024 earnings | Positive | -1.5% | Revenue doubled and gross margin improved despite higher operating expenses. |
Earnings releases have often seen negative or muted price reactions, even when operational metrics improved, with only one of the last five earnings events aligning positively with the news tone.
Over the last five earnings releases, 60 Degrees Pharmaceuticals has highlighted recurring revenue growth and expanding ARAKODA® utilization, but also persistent operating losses and rising expenses. Price reactions have frequently been negative even when results appeared operationally constructive. In this Q1 2026 update, net product revenues were essentially flat while gross profit declined and operating expenses and net loss increased, fitting the pattern of ongoing profitability challenges despite earlier growth-focused quarters and financing activity.
Historical Comparison
In the past, SXTP’s earnings headlines produced an average move of about 0.5%, often skewing negative despite growth metrics. Today’s Q1 2026 update, with flat revenue and higher losses, fits a cautious pattern of investor responses to its financial results.
Recent earnings have shown recurring revenue and gross profit gains offset by sustained operating losses. Earlier quarters emphasized rapid ARAKODA® growth and improving margins; this Q1 2026 report marks a pause in revenue momentum with higher expenses and net loss, extending the company’s profitability challenge trend.
Market Pulse Summary
This announcement details Q1 2026 results with net product revenues around $162 thousand, lower gross profit of about $76 thousand, operating expenses near $2.17 million, and a net loss of roughly $2.21 million or $1.28 per share. Compared with prior earnings reports that highlighted stronger revenue growth, this quarter underscores persistent operating losses and expense pressure. Observers may focus on future revenue trends, gross margin progression, and any financing updates in upcoming filings and earnings cycles.
AI-generated analysis. Not financial advice.
WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today reported its financial results for the first quarter of fiscal year 2026, ended March 31, 2026.
Financial Highlights for the Quarter Ended March 31, 2026:
- Net product revenues decreased approximately
1% from$164 thousand for the first quarter of 2025 to approximately$162 thousand for the first quarter of 2026. - The Company achieved a gross profit of approximately
$76 thousand in the first quarter of 2026, compared with a gross profit of approximately$90 thousand in the first quarter of 2025. - Operating expenses were approximately
$2.17 million in the first quarter of 2026, compared with approximately$2.09 million in the first quarter of 2025. - Net loss attributable to common shareholders in the first quarter of 2026 was approximately
$2.21 million , or a net loss of$1.28 per share, compared with a net loss of approximately$2.00 million , or a net loss of$6.25 per share, in the first quarter of 2025.
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine) in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Australian Chestnut Extract and/or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 30, 2026, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Media Contact:
Sheila A. Burke
SheilaBurke-consultant@60degreespharma.com
(484) 667-6330
Investor Contact:
Patrick Gaynes
patrickgaynes@60degreespharma.com
(310) 989-5666
